The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding (NCT02385422) | Clinical Trial Compass
UnknownPhase 4
The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding
China480 participantsStarted 2015-03
Plain-language summary
To compare the efficacy and safety of Carvedilol and Propranolol in patients with cirrhosis-related esophagogastric varices after multiple endoscopic treatments for secondary prophylaxis.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* age between 18-70 years old;
* cirrhotic patients referred to Zhongshan Hospital with esophagogastric varices confirmed by endoscopy;
* history of variceal bleeding; at least 3 times of endoscopic treatment;
* with 1) mild esophageal varices;2) gastric varices with a diameter less than 5mm; or 3) variceal eradication at the time of recruiting.
Exclusion Criteria:
Patients are excluded when they have
* episodes of variceal bleeding after the last endoscopic treatment;
* diagnosis of hepatic cellular carcinoma;
* severe systemic diseases;
* refractory ascites;
* contraindication to Carvedilol or Propranolol, such as: asthma, chronic obstructive pulmonary disease, allergic rhinitis, New York Heart Association IV chronic heart failure, atrioventricular blockade, severe bradycardia(HR\<50bpm), sick sinus syndrome, cardiogenic shock, severe hypotension(ABPsys\<85mmHg);
* previous and continued use of β-blockers;
* Child -Pugh Class C.